DuPont de Nemours, Inc. (DD) | The Buildout — AI Infrastructure
The Verdict
DuPont makes specialty membranes, ion-exchange resins, and engineered materials used in healthcare, water treatment, construction, and industrial markets. In the AI infrastructure buildout, its clearest role is the ultra-pure water systems, reverse-osmosis elements, and ion-exchange resins supplied to semiconductor fabs. Management describes this as a fast-growing niche, but DuPont is a derivative supplier to chipmakers rather than a primary AI hardware or software vendor.
| Market Cap | — |
| Revenue (TTM) | $9.7B |
| Revenue Growth | −20.4% |
| EBITDA Margin (TTM) | 23.4% |
| Net Debt | $2.4B |
| Earnings Beats | 7 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Semiconductor ultra-pure water grew 20%-plus for several quarters, and management expects that pace to continue.
- Q2 2026 transaction-adjusted free cash flow came in at a 127% conversion rate; full-year conversion is guided much closer to 100% than 90%.
- Full-year 2026 organic growth was raised twice, to slightly ahead of 4%, with H2 guided to ~6% on carry-forward pricing.
- Q2 operating EBITDA margin was 24.6%, up 80 basis points despite a 30-basis-point price/cost headwind.
- EV battery adhesives revenue is about $70M today, with management expecting it to move into the triple digits in 2026–27.
What We’re Watching
- Q4 2026 carries the biggest step-up: total company organic growth is guided to ~7%, tied to global water projects and H2 pricing.
- Water full-year organic growth was revised from mid-single to low-to-mid single digits because of Middle East timing.
- H2 margin guidance embeds a 50-basis-point oil/gas inflation headwind; raw-material inflation beyond the ~$90M pricing offset is a risk.
- 80/20's disclosed H2 benefit is only a few million in EBITDA; scaling beyond the first four Diversified Industrials businesses is unproven.
Thesis is intact but bounded. Two consecutive beats-and-raises, 127% quarterly cash conversion, and pricing already in place support execution; the water-growth cut is acknowledged and offset at the total company level. The key open question is whether the Q4 water projects deliver the guided ~7% organic step-up without further Middle East disruption or a second inflation wave.
Earnings Beat
DuPont reported Q2 2026 net sales of $1.8B, up 4% organic. Operating EBITDA was $448M, up 8% year over year, with an operating EBITDA margin of 24.6%. Transaction-adjusted free cash flow was $326M, representing 127% conversion.
| Metric | Q1 FY2026 | Q4 FY2025 | Q1 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $1.7B | $1.7B | $3.1B | −45.2% |
| Gross margin | 35.8% | 31.1% | 32.6% | +320bps |
| EBITDA | $254M | $386M | $787M | −67.7% |
| EPS | $1.17 | $-0.91 | $-4.22 | −127.7% |
| Transaction-adjusted free cash flow | $326M | $147M | n/a | — |
We have the extra 2 points of pricing that kind of gets you to the 6% organic growth that we see in the second half of the year. So no significant uplift needed there to achieve that target.— Antonella Franzen, CFO, Aug. 4, 2026
Management tone: Management raised guidance again and framed the second-half acceleration as mostly carry-forward pricing already in place, not an assumed demand inflection. It acknowledged the Water full-year growth cut while emphasizing healthcare and total-company strength.
Management Guidance
Q3 2026 guidance is net sales $1.835B, organic ~5% adjusted for prior-year timing and ~3% as reported, operating EBITDA $448M, margin 24.4% including a 50-basis-point oil/gas inflation headwind, and adjusted EPS $1.80–$1.90. H2 guidance is net sales midpoint $3.675B, organic ~6%, operating EBITDA $900M, and adjusted EPS midpoint $3.73. FY2026 guidance includes organic growth slightly ahead of 4%, operating EBITDA midpoint $1.760B, adjusted EPS midpoint $7.24, and FCF conversion ahead of 90% / much closer to 100%.
Trajectory
Reported revenue reset lower after the Nov. 1, 2025 Qnity separation, then stabilized: Q1 2026 net sales were $1,681M with 2% organic growth, and Q2 2026 net sales were $1.8B with 4% organic growth. Management guides H2 to ~6% organic, driven by carry-forward pricing and Q4 water projects, and full-year operating EBITDA margin to 24.5%.
The Model
The model projects FY+1 revenue of $7,215M and EBITDA of $1,760M, a 24.4% margin. FY+2 revenue rises to $7,560M with EBITDA of $1,928M, a 25.5% margin. The near-term projection is anchored by the company's full-year operating EBITDA guide; the outyear reflects continued modest growth and margin expansion from productivity.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $11.1B | $7.2B | $7.6B |
| YoY Growth | — | −34.9% | +4.8% |
| EBITDA | $2.8B | $1.8B | $1.9B |
| EBITDA Margin | 25.3% | 24.4% | 25.5% |
Projections are the median of 5 independent model runs. The model’s revenue sits 1.5% above analyst consensus.
Q3 2026 guidance is net sales $1.835B, organic ~5% adjusted for prior-year timing and ~3% as reported, operating EBITDA $448M, margin 24.4% including a 50-basis-point oil/gas inflation headwind, and adjusted EPS $1.80–$1.90. H2 guidance is net sales midpoint $3.675B, organic ~6%, operating EBITDA $900M, and adjusted EPS midpoint $3.73. FY2026 guidance includes organic growth slightly ahead of 4%, operating EBITDA midpoint $1.760B, adjusted EPS midpoint $7.24, and FCF conversion ahead of 90% / much closer to 100%.
What Could Go Right — and Wrong
- Q4 water projects deliver on schedule, taking total company organic growth to ~7% in Q4 and full-year growth above 4%.
- Semiconductor ultra-pure water growth of 20%-plus continues or broadens across ion exchange and reverse-osmosis products.
- 80/20 scales beyond the first four Diversified Industrials businesses, moving from a few million of H2 EBITDA to structural margin improvement.
- EV battery adhesives grow from about $70M today into triple digits across 2026–27.
- Portfolio shift toward management's two-thirds Healthcare & Water / one-third Diversified Industrials target progresses.
- Middle East conflict or project delays push water revenue beyond Q4, leaving Water full-year growth below low-to-mid single digits.
- Raw-material inflation outruns the ~$90M pricing offset, adding more than the guided 50-basis-point H2 oil/gas margin headwind.
- The Q4 ~7% organic step-up fails if contracted water projects slip or the pricing bridge erodes.
- EV battery adhesive growth slips if automotive OEM program launches are delayed.
- 80/20 produces revenue walkaways or its H2 benefit remains only a few million in EBITDA.
Looking Ahead
The next 12 months hinge on Q3 execution, the Q4 water-project ramp, and whether the pricing-led H2 bridge converts. Management expects the 3% COGS productivity run rate within about 18 months, sales-force commission pay in 2027, and Edina Gen4 reverse-osmosis commercialization in 2027, with Healthcare and Water M&A possible.
- Q3 2026Q3 2026 earnings — Tests $1.835B revenue and ~3% organic as reported before the Q4 step-up.
- Q4 2026Q4 water project delivery — Large Middle East and global water projects expected mostly Q4; drives ~7% organic.
- FY2026Full-year guidance result — Organic slightly ahead of 4%; operating EBITDA midpoint $1.760B.
- 2027Edina Gen4 RO commercialization — Next-generation reverse-osmosis capacity expected to commercialize.
- 2027Sales force commission pay — Sales force moves to commission-based pay in 2027.
- ~20273% COGS productivity run-rate — Net productivity target of 3% of COGS annual reduction within ~18 months.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $12.1B | $11.1B | $9.7B | -8.0% |
| Gross Margin | 32.0% | 32.9% | 33.8% | +90bps |
| EBITDA | $3.0B | $2.8B | $48.3B | -5.2% |
| EBITDA Margin | 24.5% | 25.3% | 23.4% | +75bps |
| Net Income | $704M | −$779M | −$29M | -210.7% |
| Free Cash Flow | $1.3B | $1.1B | $4.0B | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)33.8%
- EBITDA Margin (TTM)23.4%
- Net Margin (TTM)-0.3%
- ROIC7.1%
- FCF Conversion48.8%
- SBC / Revenue0.1%
The Company
DuPont de Nemours is a diversified industrial and specialty-materials company organized into Healthcare & Water Technologies and Diversified Industrials. Its products include TYVEK® medical packaging, TYCHEM® protective suits, AMBERLITE™ ion-exchange resins, FILMTEC™ reverse-osmosis elements, and BETAFORCE™/BETASEAL™ structural adhesives. It is not an AI-hardware or AI-software company; its direct AI-infrastructure link is the ultra-pure water systems, reverse-osmosis elements, and ion-exchange resins supplied to semiconductor fabs.
DuPont runs one business system across segments, targeting net productivity of 3% of COGS annually within about 18 months and simplifying portfolios through 80/20. Q1 2026 net sales by geography were roughly 46% United States, 24% Asia Pacific, 23% EMEA, and 8% Other. It has disclosed no new greenfield capacity but is expanding existing assets, including Edina, Minnesota reverse-osmosis capacity.
Business Segments
Competitive Landscape
DuPont frames its competitive position around differentiated products — medical packaging, biopharma components, reverse-osmosis elements, ion-exchange resins, and EV battery adhesives — rather than commodity scale. The source material's wiring output lists 13 competitor relationships but does not name them in the provided text; no sole-source position is disclosed.
Supply Chain
DuPont sits downstream of specialty-chemical inputs such as amines and upstream of semiconductor, water-treatment, and industrial end markets. No reviewed neighbor transcript directly named DuPont; the documented tie is Huntsman's amines-customer list.
More on DD: Earnings recap